Abstract

We have successfully built a novel DNA vector platform, which is uniquely suited for gene and cellular therapy — it provides persistent expression and episomal maintenance without the use of potentially toxic viral components or the risk of insertional mutagenesis. We have demonstrated its utility in a range of applications in vitro, ex vivo, and in vivo. This DNA vector platform allows the design of clinically relevant episomally replicating DNA vectors that can be used to confer sustained expression of corrective genes and can be compared in application to established integrating vector and gene editing systems. This presentation will provide an overview of this DNA vector system and its applications that could potentially have an enormous impact in a range of fields including DNA vaccines, gene therapy and the clinical application of recombinant T Cell Immunotherapy and personalised stem-cell medicine